Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BTRC 4017A |
Synonyms | |
Therapy Description |
BTRC 4017A is a bispecific antibody that targets both Erbb2 (Her2) and CD3, which may lead to CTL-dependent killing of Erbb2 (Her2)-expressing tumor cells (PMID: 30442682). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BTRC 4017A | BTRC4017A|RG6194 | CD3 Antibody 74 HER2 (ERBB2) Antibody 59 | BTRC 4017A is a bispecific antibody that targets both Erbb2 (Her2) and CD3, which may lead to CTL-dependent killing of Erbb2 (Her2)-expressing tumor cells (PMID: 30442682). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03448042 | Phase I | BTRC 4017A | A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | 8 |